Cargando…
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors
Intratumor mutational heterogeneity has been documented in primary non-small-cell lung cancer. Here, we elucidate mechanisms of tumor evolution and heterogeneity in metastatic thoracic tumors (lung adenocarcinoma and thymic carcinoma) using whole-exome and transcriptome sequencing, SNP array for cop...
Autores principales: | Roper, Nitin, Gao, Shaojian, Maity, Tapan K., Banday, A. Rouf, Zhang, Xu, Venugopalan, Abhilash, Cultraro, Constance M., Patidar, Rajesh, Sindiri, Sivasish, Brown, Anna-Leigh, Goncearenco, Alexander, Panchenko, Anna R., Biswas, Romi, Thomas, Anish, Rajan, Arun, Carter, Corey A., Kleiner, David E., Hewitt, Stephen M., Khan, Javed, Prokunina-Olsson, Ludmila, Guha, Udayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461561/ https://www.ncbi.nlm.nih.gov/pubmed/30840888 http://dx.doi.org/10.1016/j.celrep.2019.02.028 |
Ejemplares similares
-
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
por: Biswas, Romi, et al.
Publicado: (2016) -
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020) -
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma
por: Venugopalan, Abhilash, et al.
Publicado: (2021) -
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021) -
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential
por: Butler, Kelly, et al.
Publicado: (2023)